The round pushed the overall funding for the Novartis-backed autoimmune and neurodegenerative disorder drug developer past $250m.
Annexon, a US-based biopharmaceutical company backed by pharmaceutical firm Novartis, completed a $100m financing round yesterday led by hedge fund manager Redmile Group.
Deerfield Management, Eventide Asset Management, Farallon Capital Management, Janus Henderson Investors and Logos Capital also took part in the round as new investors, along with funds and accounts managed by BlackRock.
The round was filled out by existing shareholders Adage Capital Partners, Bain Capital Life Sciences, Blackstone Life Sciences, New Enterprise Associates (NEA), Satter Medical Technology Partners…
